Dosimetric feasibility of stereotactic ablative radiotherapy in pulmonary vein isolation for atrial fibrillation using intensity-modulated proton therapy

Xue-Ying Ren1,# | Peng-Kang He2,# | Xian-Shu Gao1 | Zhi-Lei Zhao3 | Bo Zhao1 | Yun Bai1 | Si-Wei Liu1 | Kang Li2 | Shang-Bin Qin1 | Ming-Wei Ma1 | Jing Zhou2 | Yi Rong4

1Department of Radiation Oncology, Peking University First Hospital, Beijing, China
2Department of Cardiology, Peking University First Hospital, Beijing, China
3Department of Radiation Oncology, Yizhou International Proton Therapy Medical Center, Hebei, China
4Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA

Abstract

Purpose: To evaluate dosimetric properties of intensity-modulated proton therapy (IMPT) for simulated treatment planning in patients with atrial fibrillation (AF) targeting left atrial-pulmonary vein junction (LA-PVJ), in comparison with volumetric-modulated arc therapy (VMAT) and helical tomotherapy (TOMO).

Methods: Ten thoracic 4D-CT scans with respiratory motion and one with cardiac motion were used for the study. Ten respiratory 4D-CTs were planned with VMAT, TOMO, and IMPT for simulated AF. Targets at the LA-PVJ were defined as wide-area circumferential ablation line. A single fraction of 25 Gy was prescribed to all plans. The interplay effects from cardiac motion were evaluated based on the cardiac 4D-CT scan. Dose-volume histograms (DVHs) of the ITV and normal tissues were compared. Statistical analysis was evaluated via one-way Repeated-Measures ANOVA and Friedman’s test with Bonferroni’s multiple comparisons test.

Results: The median volume of ITV was 8.72 cc. All plans had adequate target coverage ($V_{23.75\text{Gy}} \geq 99\%$). Compared with VMAT and TOMO, IMPT resulted in significantly lower dose of most normal tissues. For VMAT, TOMO, and IMPT plans, $D_{\text{mean}}$ of the whole heart was 5.52 ± 0.90 Gy, 5.89 ± 0.78 Gy, and 3.01 ± 0.57 Gy ($P < 0.001$), mean dose of pericardium was 4.74 ± 0.76 Gy, 4.98 ± 0.62 Gy, and 2.59 ± 0.44 Gy ($P < 0.001$), and $D_{0.03\text{cc}}$ of left circumflex artery (LCX) was 13.96 ± 5.45 Gy, 14.34 ± 5.91 Gy, and 8.43 ± 7.24 Gy ($P < 0.001$), respectively. However, no significant advantage for one technique over the others was observed when examining the $D_{0.03\text{cc}}$ of esophagus and main bronchi.

Conclusions: IMPT targeting LA-PVJ for patients with AF has high potential to reduce dose to surrounding tissues compared to VMAT or TOMO. Motion mitigation techniques are critical for a particle-therapy approach.

KEY WORDS

atrial fibrillation, helical tomotherapy, intensity-modulated proton therapy, stereotactic ablative radiotherapy, volumetric-modulated arc therapy

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine
INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac arrhythmia\(^1\) mostly caused by ectopic beats initiated mostly from the pulmonary veins (PVs) entering the left atrium.\(^2\) A well-established approach for treatment of symptomatic drug-refractory patients with AF is catheter ablation (CA) by generating electrical isolation of the left atrial-pulmonary vein junction (LA-PVJ) which includes radiofrequency ablation and freeze ablation.\(^3\) However, ablation procedures are invasive, complicated, and requires sufficient training and experience. The risk of congestive heart failure, stroke, bleeding, and complications of CA increase hospitalizations rate.\(^4\) The incidence of major complications with CA, including bleeding, atrioesophageal fistula, pericarditis, cardiac tamponade/perforation, and even death,\(^5\) is approximately 5%.\(^5\)\(^–\)7 In patients with paroxysmal and nonparoxysmal AF, the overall 1-year recurrence rate after single procedure is about 40% or more.\(^8\)

Stereotactic ablative radiotherapy (SABR) is a matured treatment technique that delivers precise and intense radiation dose in one or a few fractions while minimizing damage to surrounding tissues.\(^9\) Successful adaptation of SABR to target cardiac sarcoma has been reported.\(^10\) Preclinical studies exploring SABR using various forms of particle therapy for cardiac ablation have demonstrated histological changes and electrophysiological effects (voltage/potential amplitude or bidirectional block).\(^11\)\(^–\)18 Using heavy ion-based radioablation for healthy pigs, Lehmann and Rapp et al. demonstrated radiation-induced fibrosis, microvascular damage, and chronic inflammation.\(^11\)\(^–\)17 Successful clinical treatments for malignant ventricular tachycardia or recurrent paroxysmal AF have also been reported.\(^19\)\(^–\)32 Therefore, SABR may be a novel and noninvasive approach for AF.

However, delivering one concentrated dose to the cardiac region can be challenging due to cardiac motion and its close proximity to critical structures. Compared to ventricular tachycardia, previous studies showed that SABR was considered more challenging for AF patients, and the reasons are multifold: (a) creating electrical isolation of the LA-PVJ requires a significantly complex target; (b) it is unclear whether single fraction 25 Gy is adequate; and (c) the close proximity of esophagus and bronchus to the target may be a limiting factor.\(^33\)\(^–\)35 In addition, long-term follow-up in some clinical trials for patients with breast cancer has shown that radiotherapy can increase the subsequent rate of ischemic heart disease, presumably through incidental exposure of the heart to ionizing radiation.\(^36\) Several studies revealed that radiation dose to the heart in lung cancer patients was associated with the risk of cardiac events\(^37\)\(^–\)41 and overall survival.\(^37\)\(^–\)42\(^–\)45 While cardiotoxicity is usually considered as a latent event after 10 years, acute toxicity has also been observed early after radiotherapy.\(^36\)\(^,\)44

Previous reports of non-invasive ablative radiation for ventricular tachycardia or recurrent paroxysmal AF used photon-based treatment plans, i.e., volumetric-modulated arc therapy (VMAT) or Cyberknife.\(^19\)\(^–\)22\(^,\)32 It has been shown that single-fraction ablative radiotherapy significantly reduced burden of AF and ventricular tachycardia, but some cardiac complications, i.e., pericarditis and heart failure exacerbation, have also occurred early upon treatment completion.\(^20\) As opposed to photon-delivery techniques, intensity-modulated proton therapy (IMPT) takes advantage of proton beam’s unique Bragg Peak property and high-dose conformity with pencil beam modulation, thus may be a promising alternative for AF patients. However, IMPT is highly sensitive to tissue motion, resulting in interplay effects between treatment beams and intrafractional target motion, which could produce dosimetric cold or hot spots.\(^46\) Hohmann et al. reported possible decrease in left ventricular function after proton beam therapy in 20 swine and the adverse effect was dose dependent.\(^47\) This study aimed to investigate dosimetric properties of IMPT for non-invasive AF ablation in comparison with photon-base treatment techniques (including VMAT and TOMO) and the interplay effects in IMPT plan from cardiac motion.

METHODS

2.A CT simulation

The study has been reviewed and approved by the institutional review board (No. 2019[240]). We retrospectively collected 11 thoracic 4D computed tomography (CT) scans from our institution, of which 10 were stamped with respiratory motion phases (patients 1–10) and 1 was stamped with cardiac motion phases (patient 11). All had received 2 thoracic 4D-CT scans, first without and with intravenous contrast immediately thereafter. The thoracic respiratory 4D-CT images were taken on a 16-slice Brilliance Big Bore CT (Philips Medical Systems, Cleveland, OH, USA) and respiratory motion was traced by a pressure sensor belt. Each 4D-CT image consists of 10 phases 3D-CT datasets equally divided 10% of breathing phases in a complete respiratory cycle. Cardiac-gated 4D-CT images were taken on a 64-slice scanner (GE Healthcare, Waukesha, USA) at the end-expiration breath-hold using retrospective cardiac gating and also reconstructed 10 phases of cardiac cycle. For all patients, CT simulation was performed at 3-mm intervals.

2.B Delineation of targets and organs at risk (OARs)

The clinical target volume (CTV) was created aiming at LA-PVJ as wide-area circumferential ablation line (WACA) on each phase and generated 3D clinical target volumes ensuring continuity, including left CTV (CTVL) and right CTV (CTVR), WACA was the routine volume in catheter ablation for AF. The ITV was generated from combining CTVs from 10 phases in view of maximum range of respiratory or cardiac motion. The volumes of CTV and ITV were generated 3D clinical target volumes ensuring continuity, including esophagus, spinal cord, total lung, main bronchi, whole heart, pericardium, four great vessels (pulmonary artery, aorta, superior vena, and inferior vena
cava), and eight cardiac substructures. These were also contoured on all phases of the cardiac-gated 4D-CT.

Cardiac substructures covered four cardiac chambers (atria and ventricles) and four coronary arteries (left main coronary artery [LMC], left anterior descending artery [LAD], left circumflex artery [LCX], and right coronary artery [RCA]). All cardiac substructures were outlined according to previous published cardiac atlas. All the targets and OARs were contoured by one experienced radiation oncologist and evaluated by one senior cardiac electrophysiologist.

2.C Treatment planning

The AIP dataset was used to create all photon and proton plans for 10 patients about respiratory motion. A single fraction of 25 Gy was used as the prescription for all plans. For the photon plans, PTV was expanded uniformly 3 mm from ITV and physical dose of 25 Gy was prescribed to the PTV; while a total dose of 25 GyE (relative biological effectiveness 1.1) was prescribed to ITV for the proton plans. Normal tissue constraints include 0.03 cc of spinal cord, esophagus, and main bronchi receiving no more than 10 Gy, 16 Gy, and 20.2 Gy, respectively, and total lung V20 ≤ 10%, V2.5 ≤ 50%, and V7 Gy < 1500 cc. The dose to the sensitive structures was minimized, with the following priorities settings (high to low): 1 = spinal cord, 2 = esophagus, 3 = main bronchi, and 4 = total lung. Despite no hard constraints for cardiac dose exposures, we try the best to minimize dose of whole heart, pericardium, and all cardiac substructures.

All VMAT, TOMO, and IMPT plans were created blindly without prior knowledge to the quality of others. All three plans were reviewed by senior physicists and approved by one attending physician based on target goals and normal tissue constraints. VMAT plans were generated using double-full arcs on Eclipse treatment planning system (Eclipse, Version 13.5, Varian Medical Systems, Palo Alto, CA). For the TOMO plans, a field width of 1.048 cm, pitch of 0.287, and modulation factor of 3.0 were used on the HD™ treatment planning system (Version 5.1.1.6, Accuray, Sunnyvale, CA). IMPT plans were created using four beams based on IBA Proteus®PLUS machine model using pencil beam scanning. The dose distribution was calculated by the Monte Carlo algorithm on RayStation treatment planning system (Version 7.0, RaySearch Laboratories, Stockholm, Sweden), with robust optimization to cover 99% of ITV. Set-up error was determined at 3 mm, and the range uncertainty at 3.5% in addition to a distal margin of 2 mm. The spot size sigma varies between 2.6 and 7.2 mm in the energy range 70–230 MeV.

When evaluating interplay effects in IMPT plans, we calculated an IMPT nominal plan with the same optimized approach as mentioned above. A “dynamic dose” was calculated using in-house Python scripts in RayStation for evaluating interplay effects from cardiac motion. The calculation parameters used for the IMPT nominal plan included: (a) patient cardiac cycle 1.0 s; (b) spot delivery time 4.0ms/MU; (c) spot motion speed 250 cm/s; (d) energy layer shift time 2.0 s; and (v) starting phase T00 (0% phase of cardiac cycle). The final dose distribution was accumulated on the AIP CT.
images from 10 cardiac motion phases with equal weighting using deformable image registration algorithm in RayStation system.

2.D | Evaluation

For evaluating target displacements of cardiac motion, the maximal displacements for centroids of CTVL and CTVR at all phases of cardiac-gated 4D-CT were recorded in medial-lateral (ML), anterior-posterior (AP), and superior-inferior (SI) direction, in reference to phase T00.

For dosimetric evaluation, dose-volume histograms (DVHs) and dose distributions were calculated for ITV and other critical structures, such as the whole heart, pericardium, cardiac substructures, total lung, esophagus, main bronchi, and spinal cord. For pair comparison, all plans were normalized to 100% of prescription dose (25GyE) covering 99% ITV.

2.E | Statistical analysis

Data distribution was analyzed using Shapiro-Wilk test. One-way Repeated-Measures ANOVA with Bonferroni’s multiple comparisons test was performed for normal distribution data. Data showing non-normal distribution was compared using Friedman’s test with Bonferroni’s multiple comparisons test. A p value of 0.05 or less was considered to indicate statistical significance. SPSS 24.0 statistical software (IBM SPSS Inc., Armonk, NY) was used for statistical analyses.

3 | RESULTS

3.A | Treatment planning study for respiratory motion

For patients 1–10, median volumes of CTV, ITV, and PTV were 2.62 cc (min: 1.71 cc, max: 3.37 cc), 8.72 cc (min: 5.36 cc, max: 12.60 cc), and 30.16 cc (min: 20.53 cc, max: 36.44 cc), respectively. The median ratio of CTV to ITV was 32% (min: 21%, max: 55%). All plans provided adequate target coverage (V23.75 Gy ≥ 99%). ITV V23.75 Gy (%) was 99.92 ± 0.13, 99.86 ± 0.19, and 99.70 ± 0.20 for VMAT, TOMO, and IMPT plans, respectively. The dose distribution for one case is shown in Fig. 2.

As for normal tissues, dosimetric parameters of three modalities for critical structures (including total lung, spinal cord, esophagus, and main bronchi) are given in Table 1. DVH analysis showed significantly lower mean dose and V5 to the total lung with the IMPT plans, compared with VMAT and TOMO plans. For IMPT plans, mean dose, D5cc to the esophagus, and maximum dose to the spinal cord were significantly reduced by 0.94 Gy, 2.29 Gy, and 3.03 Gy, respectively, compared with VMAT. However, D10cc of esophagus (~14.9 Gy) and main bronchi (~11.3 Gy) was comparable in all three plans.

The dosimetric parameters for the rest of unconventional critical structures (including whole heart, pericardium, individual cardiac chambers, and four main coronary arteries (LMC, LAD, LCX, and RCA)) are shown in Table 2. Compared with VMAT or TOMO, IMPT improved Dmean, V2, V5, and V10 of the whole heart and pericardium. Compared with VMAT and TOMO plans, IMPT reduced Dmean, and V5 of the whole heart by 2.51 Gy and 2.88 Gy, 23.65% and 23.15%, respectively, which also reduced Dmean and V5 of pericardium by 2.15 Gy and 2.39 Gy, 18.94% and 18.91%, respectively. In addition, for IMPT plans, Dmean of four cardiac chambers was significantly lower than VMAT and TOMO plans.

Dose-volume histograms analysis of V2, V5, V10, V15, and V20 of four cardiac chambers and four main coronary arteries was shown in Fig. 3. When comparing IMPT with VMAT and TOMO plans, the difference in V5 for left ventricle was 14.11% and 10.01%; and the differences in D0.03cc for LMC, LAD, LCX, and RCA were 8.03 Gy and 8.34 Gy, 6.91 Gy and 5.25 Gy, 5.53 Gy and 5.91 Gy, and 5.10 Gy and 4.55 Gy, respectively.

3.B | Treatment planning study for cardiac motion

For patient 11, the maximal displacements of CTVL in ML, AP, and SI directions due to cardiac motion were 2.0, 1.0, and 2.4 mm, and the maximal displacements of CTVR were 0.7, 0.5, and 1.2 mm, respectively. DVHs comparisons between IMPT nominal plan and dynamic dose considering interplay effects were shown in Fig. 4. V23.75 Gy and homogeneity index (HI = D5%/D95%) of ITV in IMPT nominal plan and interplay effects were 99.80% and 99.83%, 1.09 and 1.10, respectively. For this patient, the impact of interplay effects on OARs doses was almost negligible for the robustly optimized IMPT plan.

4 | DISCUSSION

To our knowledge, this study is the first treatment planning investigation to compare detailed dose distribution using proton beams, as compared with photon plans, for targeting at LA-PVJ with the catheter-free procedures to ablate AF. It demonstrates that all plans can achieve adequate target coverage for precise circumferential and electrical isolation of the LA-PVJ. Our findings also show that compared with VMAT and TOMO, IMPT improved the sparing of normal cardiac structures at most of dose level, not including the maximum dose of esophagus and main bronchi.

Stereotactic ablative radiotherapy may be a viable option to overcome some shortcomings of previous treatment for AF ablation. In the past decades, it is very difficult to balance the safety and efficacy of radiofrequency ablation for AF. High recurrence risk of AF after CA is usually caused by inaccessible atrial myocardium and discontinuous ablation lines due to insufficient energy to generate transmural myocardial scar considering severe complications such as atrioesophageal fistula. Compared with conventional radiofrequency ablation, stereotactic arrhythmia radioablation could provide continuous ablation lines and adequate energy to generate...
transmural lesions for isolating electrical conduction between pulmonary veins and left atrium.

Intensity-modulated proton therapy can reduce the dose of heart and cardiac substructures and may reduce potential adverse effects. The recent phase I/II trial reported that two patients (10.5%) who received stereotactic ablative radiotherapy (IMRT or VMAT) for malignant ventricular tachycardia experienced a grade 3 treatment-related severe adverse effect.20 One patient experienced heart failure exacerbation (grade 3), and another patient had pericarditis and was treated with prednisone. These adverse events could be associated with dose exposure to the normal heart and pericardium, but it is necessary to notice that the health condition of these patients is very poor. The following secondary analysis for this trial found that the correlation between larger target volume and shorter overall survival.19 Compared with the radioablation of ventricular arrhythmias, which has been carried out in clinics, the targets in AF have high complexity, and close to critical structures. Hence, special attention should be paid to the dose of whole heart, pericardium, and cardiac substructures. A recent research found that rates of major coronary events (MCE) increased linearly with the mean dose to the heart by 7.4% per Gray, with no apparent threshold.36 A validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy showed that left ventricle volume receiving 5 GY (LV-V5) was the most important prognostic dose-volume parameter.53 For lung cancer patients underwent radiotherapy, a study showed that the rates of grade ≥3 cardiac events increased with mean heart dose by 7% per Gy.40 In our study, IMPT had the reduction of mean dose of whole heart by approximately 2.7 Gy and the LV-V5 by at least 10% compared with those photon plans. Another study found that the risk of pericardial effusion (PCE) was related to several cardiac parameters (e.g., mean dose of whole heart / pericardium, heart / pericardium V5), and PCE rate increased with mean dose of pericardium by 5% per Gy.37 Our study showed decreased mean dose of pericardium, heart V5, and pericardium V5 by about 2.3 Gy, 23% and 19%, respectively, with IMPT.

Previous study found that mean dose, V5 and V30 to LAD were related to acute coronary syndrome or congestive heart failure after conventional-dose chemoradiation therapy for lung cancer.54 Another study showed that coronary artery-based model, including LAD-V5 and LCX-V20, was superior to the whole heart when analyzing late ischemic cardiotoxicity.55 In our study, IMPT significantly reduced doses to the four main coronary arteries. Except for the LCX, the mean dose of main coronary arteries was almost zero and the maximum dose was no more than 2.0 Gy. Compared with VMAT and TOMO plans, IMPT reduced Dmean, D0.03cc, and V5 of LCX by 7.19 Gy and 4.83 Gy, 5.53 Gy and 5.91 Gy, 78.85% and 50.83%, respectively. Nevertheless, there were currently no exact dose

**Fig. 2.** An example of dose distribution of VMAT (a), TOMO (b), and IMPT (c) for the same patient. The green lines and inner dark-blue lines outlined PTV and ITV

**Table 1** DVH parameters (Mean ± SD) of the adjacent normal tissues

| Parameters       | VMAT     | TOMO     | IMPT     | p1 (VMAT vs. IMPT) | p2 (TOMO vs. IMPT) | p3 (VMAT vs. TOMO) |
|------------------|----------|----------|----------|-------------------|-------------------|-------------------|
| Total Lung       | Dmean(Gy)| 2.31 ± 0.54 | 2.27 ± 0.41 | 1.26 ± 0.38 | <0.001 | <0.001 | 1.000 |
| V5 (%)           | 15.08 ± 6.17 | 14.77 ± 4.23 | 9.65 ± 2.92 | 0.005 | <0.001 | 1.000 |
| V20 (%)          | 0.10 ± 0.05 | 0.27 ± 0.13 | 0.41 ± 0.35 | 0.001 | 1.000 | 0.005 |
| Spinal Cord      | D0.03cc(Gy) | 8.25 ± 1.81 | 6.64 ± 0.78 | 5.22 ± 1.29 | <0.001 | 0.076 | 0.076 |
| Esophagus        | Dmean (Gy) | 2.40 ± 0.38 | 1.98 ± 0.46 | 1.46 ± 0.44 | <0.001 | 0.076 | 0.076 |
| D0.03cc(Gy)a     | 14.33 ± 0.37 | 14.93 ± 0.83 | 14.88 ± 0.90 | <0.001 | 0.221 | 0.042 |
| D5cc (Gy)        | 4.79 ± 1.66 | 3.49 ± 1.83 | 2.50 ± 1.45 | <0.001 | 0.076 | 0.076 |
| Main Bronchi     | D0.03cc(Gy)a | 10.41 ± 4.64 | 11.79 ± 4.07 | 11.34 ± 4.77 | <0.001 | 0.221 | 0.042 |

V5 (%) means the percentage of volume receiving at least 5 (Gy) doses. Dn (Gy) means the maximum dose received by n % volume. Abbreviations: IMPT, intensity-modulated proton therapy; ITV, internal target volume; TOMO, helical tomotherapy; VMAT, volumetric-modulated arc therapy.

aThere was no significant difference of D0.03cc to esophagus and main bronchi among three groups, so we did not do paired test.
patients would be treated under respiratory gating, we used the respiratory-phased binned 4D-CT for dosimetric comparison among three modalities in our study, which is the same as previous clinical studies. In our study, we found that the median ratio of CTV to ITV is 32%. Therefore, ITV might be reduced by 68% if respiratory-gated treatment is applied. The previous work found that displacements of LA-PVJ were mainly affected by respiratory motion, and the mean displacements were 1–4 mm caused by cardiac contraction under breath-hold conditions. A recent publication reported that the motion of cardiac substructures is not uniform and patient specific. Even with appropriately compensated respiratory motion using various techniques, including gating, tracking, and/or breath-holding, cardiac motion-induced anatomy deformation is complex, which could be partially compensated using personalized margin determined based on cardiac 4D-CT images. Interplay effects of scanned particle beams and moving targets can severely impact dose distributions. However, the D<sub>0.03cc</sub> of esophagus was not significantly improved by IMPT, due to its close proximity to targets.

Table 2: DVH parameters (Mean ± SD) of heart and cardiac substructures

| Parameters | VMAT | TOMO | IMPT | p1 (VMAT vs. IMPT) | p2 (TOMO vs. IMPT) | p3 (VMAT vs. TOMO) |
|------------|------|------|------|-------------------|-------------------|-------------------|
| Whole Heart D<sub>mean</sub>(Gy) | 5.52 ± 0.90 | 5.89 ± 0.78 | 3.01 ± 0.57 | <0.001 | <0.001 | 0.160 |
| V<sub>2</sub> (%) | 54.23 ± 10.83 | 55.69 ± 9.82 | 20.14 ± 3.05 | <0.001 | <0.001 | 0.435 |
| V<sub>5</sub> (%) | 39.16 ± 7.43 | 38.66 ± 5.68 | 15.51 ± 2.22 | <0.001 | <0.001 | 1.000 |
| V<sub>10</sub> (%) | 17.52 ± 3.05 | 20.72 ± 2.99 | 11.70 ± 1.82 | <0.001 | <0.001 | 0.034 |
| V<sub>15</sub> (%) | 10.14 ± 1.74 | 12.13 ± 2.06 | 9.05 ± 1.78 | 0.073 | 0.001 | 0.006 |
| V<sub>20</sub> (%) | 6.50 ± 1.31 | 7.96 ± 1.20 | 6.67 ± 1.78 | 1.000 | 0.038 | <0.001 |
| Pericardium D<sub>mean</sub>(Gy) | 4.74 ± 0.76 | 4.98 ± 0.62 | 2.59 ± 0.44 | <0.001 | <0.001 | 0.330 |
| V<sub>2</sub> (%) | 47.36 ± 8.94 | 47.86 ± 7.38 | 18.21 ± 2.41 | <0.001 | <0.001 | 1.000 |
| V<sub>5</sub> (%) | 32.46 ± 6.12 | 32.43 ± 4.78 | 13.52 ± 1.78 | <0.001 | <0.001 | 1.000 |
| V<sub>10</sub> (%) | 14.25 ± 2.74 | 16.91 ± 2.64 | 9.85 ± 1.43 | 0.011 | <0.001 | 0.035 |
| V<sub>15</sub> (%) | 8.13 ± 1.43 | 9.77 ± 1.61 | 7.49 ± 1.40 | 0.231 | 0.001 | 0.006 |
| V<sub>20</sub> (%) | 5.17 ± 0.98 | 6.34 ± 0.85 | 5.43 ± 1.37 | 0.983 | 0.062 | <0.001 |
| LA D<sub>mean</sub>(Gy) | 16.80 ± 2.26 | 17.48 ± 1.92 | 14.47 ± 2.86 | 0.004 | 0.002 | 0.265 |
| LV D<sub>mean</sub>(Gy) | 2.14 ± 1.22 | 1.84 ± 0.80 | 0.15 ± 0.13 | 0.001 | <0.001 | 0.597 |
| RA D<sub>mean</sub>(Gy) | 4.84 ± 2.11 | 5.58 ± 2.25 | 2.47 ± 0.93 | 0.004 | 0.001 | 0.041 |
| RV D<sub>mean</sub>(Gy) | 1.58 ± 0.70 | 1.84 ± 0.58 | 0.01 ± 0.00 | 0.022 | <0.001 | 0.539 |
| LMC D<sub>mean</sub>(Gy) | 8.44 ± 4.28 | 7.30 ± 2.83 | 0.95 ± 0.75 | 0.001 | 0.005 | 1.000 |
| D<sub>0.03cc</sub>(Gy) | 9.90 ± 4.29 | 10.21 ± 3.54 | 1.87 ± 1.42 | 0.011 | <0.001 | 1.000 |
| LAD D<sub>mean</sub>(Gy) | 3.92 ± 1.47 | 2.75 ± 0.88 | 0.19 ± 0.23 | <0.001 | 0.022 | 0.539 |
| D<sub>0.03cc</sub>(Gy) | 8.43 ± 2.37 | 6.77 ± 2.21 | 1.52 ± 1.89 | <0.001 | 0.011 | 1.000 |
| LCX D<sub>mean</sub>(Gy) | 9.93 ± 4.48 | 7.57 ± 2.04 | 2.74 ± 1.81 | <0.001 | 0.042 | 0.221 |
| D<sub>0.03cc</sub>(Gy) | 13.96 ± 5.45 | 14.34 ± 5.91 | 8.43 ± 7.24 | 0.011 | 0.042 | 1.000 |
| RCA D<sub>mean</sub>(Gy) | 3.87 ± 1.89 | 2.85 ± 1.25 | 0.04 ± 0.04 | <0.001 | 0.022 | 0.539 |
| D<sub>0.03cc</sub>(Gy) | 5.18 ± 2.06 | 4.63 ± 1.52 | 0.08 ± 0.10 | <0.001 | 0.011 | 1.000 |

Abbreviations: IMPT, intensity-modulated proton therapy; LA, left atrium; LAD, left anterior descending artery; LCX, left circumflex artery; LMC, left main coronary artery; LV, left ventricle; RA, right atrium; RCA, right coronary artery; RV, right ventricle; TOMO, helical tomotherapy; VMAT, volumetric-modulated arc therapy.
Fig. 3  Dosimetric parameters for four cardiac chambers (a) and four main coronary arteries (b) according to radiation treatment modalities. All data are shown as mean.
There are also other limitations in this study. The simulated irradiation volumes in normal cardiac images were used, instead of AF patients who usually had a nonconstant cyclical heartbeat, cardiac insufficiency, and enlarged left atrium. In addition, when implementing IMPT for animal experiments or patients with AF, there are some critical aspects that need more attention, which is not considered in this dosimetric study. Although some studies showed that 25 Gy in a single fraction could create electrical block and fibrosis for AF in animals,11,15,16 others reported that much higher doses are needed (>25 Gy) to create therapeutic effects and transmural scar.12–14 Furthermore, there could be room for dosimetric improvement at a potential sacrifice of overall longer treatment time, although we tried to achieve the best optimal plans of each type during planning in this study. For example, VMAT plan quality might be marginally improved with more noncoplanar partial arcs, instead of the 2-full-arc VMAT plans used in the presented comparison. This current study is limited without further studying those planning options among the same delivery modality. All above-mentioned issues require further mathematical modelling, phantom, and clinical evaluation, which is being investigated in our future studies.

5 | CONCLUSIONS

IMPT has high potential to reduce dose to surrounding tissues due to its sharp dose gradients but motion mitigation techniques are essential for a particle therapy approach for AF. This study sheds light on the use of proton therapy for noninvasive radiotherapy for AF.

ACKNOWLEDGMENTS

This research was supported by Beijing Natural Science Foundation (Grant No. 7182164).

CONFLICTS OF INTEREST

None.

AUTHOR’S CONTRIBUTIONS

Conception and design: XYR, PKH, XSG, YR, and JZ. Acquisition of data: XYR, ZLZ, BZ, YB, SWL, KL, SBQ, and MWM. Analysis of data: XYR. Writing the first draft of the manuscript: XYR and PKH. All authors contributed to the drafting and editing of the manuscript and approved the final version.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

1. Calkins H, Hindricks G, Cappato R, et al, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14:e275–e444.
2. Haïssaguerre M, Jaïs P, Shah DC, et al, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–666.
3. January CT, Wann LS, Alpert JS, et al, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199–e267.
4. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2009;2:362–369.
5. Marrouche NF, Dresing T, Cole C, et al, Circular mapping and ablation of the pulmonary vein for treatment of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circ Arrhythm Electrophysiol. 2009;2:362–369.
6. Spragg DD, Dalal D, Cheema A, et al, Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol. 2008;19:627–631.
7. Cappato R, Calkins H, Chen S-A, et al, Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32–38.
8. Ganesan AN, Shipp NJ, Brooks AG, et al, Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004549.
9. Benedict SH, Yenice KM, Followill D, et al, Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078–4101.

10. Solty S, Kalani MY, Cheshier SH, Szabo KA, Lo A, Chang SD. Stereotactic radiosurgery for a cardiac sarcoma: a case report. Technol Cancer Res Treat. 2008;7:363–368.

11. Zei PC, Wong D, Gardner E, Fogarty T, Maguire P. Safety and efficacy of stereotactic radioablative targeting pulmonary vein tissues in an experimental model. Heart Rhythm. 2018;15:1420–1427.

12. Lehmann HI, Graeff C, Simonelli P, et al, Feasibility study on cardiac arrhythmia ablation using high-energy heavy ion beams. Sci Rep. 2016;6:38895.

13. Bode F, Blanck O, Gebhard M, et al, Pulmonary vein isolation by radiosurgery: implications for non-invasive treatment of atrial fibrillation. Europace. 2015;17:1868–1874.

14. Blanck O, Bode F, Gebhard M, et al, Dose-escalation study for cardiac radiosurgery in a porcine model. Int J Radiat Oncol Biol Phys. 2014;89:590–598.

15. Sharma A, Wong D, Weidlich G, et al, Noninvasive stereotactic radiosurgery (CyberHeart) for creation of ablation lesions in the atrium. Heart Rhythm. 2010;7:802–810.

16. Maguire PJ, Gardner E, Jack AB, et al, Cardiac radiosurgery (CyberHeart™) for treatment of arrhythmia: physiologic and histopathologic correlation in the porcine model. Cureus. 2011;3: e32.

17. Rapp F, Simonelli P, Wiedermann J, et al, Biological cardiac tissue effects of high-energy heavy ions – investigation for myocardial ablation. Sci Rep. 2019;9:5000.

18. Lehmann HI, Richter D, Prokesch H, et al, Atrioventricular node ablation in Langendorff-perfused porcine hearts using carbon ion particle therapy: methods and an in vivo feasibility investigation for catheter-free ablation of cardiac arrhythmias. Circ Arrhythm Electrophysiol. 2015;8:429–438.

19. Knutsen NC, Samson PP, Hugo GD, et al, Radiation therapy workflow and dosimetric analysis from a phase 1/2 trial of noninvasive cardiac radioablative therapy for ventricular tachycardia. Int J Radiat Oncol Biol Phys. 2019;104:1114–1123.

20. Robinson CG, Samson PP, Moore KMS, et al, Phase I/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia. Circulation. 2019;139:313–321.

21. Cuculich PS, Schill MR, Kashani R, et al, Noninvasive cardiac radiation for ablation of ventricular tachycardia. N Engl J Med. 2017;377:2325–2336.

22. Monroy E, Azpiri J, De La Peña C, et al, Late Gadolinium Enhancement Cardiac Magnetic Resonance Imaging Post-robotic Radiosurgical Pulmonary Vein Isolation (RPVII): First Case in the World. Cureus. 2016;8:e738.

23. Krug D, Blanck O, Demming T, et al, Stereotactic body radiotherapy for ventricular tachycardia (cardiac radiosurgery): First-in-patient treatment in Germany. Strahlenther Onkol. 2020;196:23–30.

24. Zeng L-J, Huang L-H, Tan H, et al, Stereotactic body radiation therapy for refractory ventricular tachycardia secondary to cardiac lipoma: A case report. Pacing Clin Electrophysiol. 2019;42:1276–1279.

25. Scholz EP, Seidensaal K, Naumann P, Andre F, Katus HA, Debus J. Risken from the dead: Cardiac stereotactic ablative radiotherapy as last rescue in a patient with refractory ventricular fibrillation storm. HeartRhythm Case Rep. 2019;5:329–332.

26. Neuwirth R, Cvek J, Knybel L, et al, Stereotactic radiosurgery for ablation of ventricular tachycardia. Europace. 2019;21:1088–1095.

27. Haskova J, Peichl P, Pirk J, Cvek J, Neuwirth R, Kautzner J. Stereotactic radiosurgery as a treatment for recurrent ventricular tachycardia associated with cardiac fibroma. HeartRhythm Case Rep. 2019;5:44–47.

28. Jumeau R, Ozsahin M, Schwitzer J, et al, Rescue procedure for an electrical storm using robotic non-invasive cardiac radio-ablation. Radiother Oncol. 2018;128:189–191.

29. Luo BW, Solty S, Wang L, et al, Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia. Circ Arrhythm Electrophysiol. 2015;8:748–750.

30. Cvek J, Neuwirth R, Knybel L, et al, Cardiac radiosurgery for malignant ventricular tachycardia. Cureus. 2014;6:e190.

31. Mayinger M, Kovacs B, Tanadini-Lang S, et al, First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia. Radiother Oncol. 2020;152:203–207.

32. Qin PC, Azpiri JR, Dad J, et al, Noninvasive stereotactic radioablation for the treatment of atrial fibrillation: First-in-man experience. J Arrhythm. 2020;36:67–74.

33. Xia P, Kotecha R, Sharma N, et al, A treatment planning study of stereotactic body radiotherapy for atrial fibrillation. Cureus. 2016;8:e678.

34. Blanck O, Ipsen S, Chan MK, et al, Treatment planning considerations for robotic guided cardiac radiosurgery for atrial fibrillation. Cureus. 2016;8:e705.

35. Ipsen S, Blanck O, Oborn B, et al, Radiotherapy beyond cancer: target localization in real-time MRI and treatment planning for cardiac radiosurgery. Med Phys. 2014;41:120702.

36. Darby SC, Ewertz M, McGale P, et al, Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998.

37. Xue J, Han C, Jackson A, et al, Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer. Radiother Oncol. 2019;133:212–219.

38. Wang K, Eblan MJ, Deal AM, et al, Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35:1387–1394.

39. Wang K, Pearlstein KA, Patchett ND, et al, Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol. 2017;125:293–300.

40. Hess RT, Sun Y, Matuszak MM, et al, Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017;35:1395–1402.

41. Ning MS, Tang L, Gomez DR, et al, Incidence and predictors of peri-cardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;99:70–79.

42. Vivekandan S, Landau DB, Counsell N, et al, The impact of cardiac radiation dosimetry on survival after radiation therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;99:51–60.

43. Sepehri CK, DeWees TA, Rehman S, et al, Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol. 2017;12:293–301.

44. Chun SG, Hu C, Choy H, et al, Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56–62.

45. Bradley JD, Paulus R, Komaki R, et al, Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–199.

46. Li Y, Kardar L, Li X, et al, On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014;41:21721.
47. Hohmann S, Deisher AJ, Suzuki A, et al, Left ventricular function after noninvasive cardiac ablation using proton beam therapy in a porcine model. *Heart Rhythm*. 2019;16:1710–1719.

48. Kong FS, Quint L, Machty M, Bradley J. Atlases for Organs at Risk (OARs) in Thoracic Radiation Therapy. http://www.rtog.org/CoreLab/ContouringAtlases/LungAtlas.aspx. Accessed Mar, 2020.

49. Duane F, Aznar MC, Bartlett F, et al, A cardiac contouring atlas for radiotherapy. *Radiother Oncol*. 2017;122:416–422.

50. Feng M, Moran JM, Koelling T, et al, Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. *Int J Radiat Oncol Biol Phys*. 2011;79:10–18.

51. Mohan R, Das UJ, Ling CC. Empowering intensity modulated proton therapy through physics and technology: an overview. *Int J Radiat Oncol Biol Phys*. 2017;99:304–316.

52. Casella M, Dello Russo A, Riva S, et al, An ablation index operator-independent approach to improve efficacy in atrial fibrillation ablation at 24-month follow-up: a single center experience. *J Interv Card Electrophysiol*. 2020;57:241–249.

53. van den Bogaard VAB, Ta BDP, van der Schaaf A, et al, Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. *J Clin Oncol*. 2017;35:1171–1178.

54. Veyya-Raman N, Wang K, Kim S, et al, Dosimetric predictors of symptomatic cardiac events after conventional-dose chemoradiation therapy for inoperable NSCLC. *J Thorac Oncol*. 2018;13:1508–1518.

55. Hahn E, Jiang H, Ng A, et al, Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. *Int J Radiat Oncol Biol Phys*. 2017;98:1116–1123.

56. Cox BW, Jackson A, Hunt M, Blisky M, Yamada Y. Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys*. 2012;83:e661–e667.

57. Grimm J, LaCouture T, Croce R, Yeo I, Zhu Y, Xue J. Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. *J Appl Clin Med Phys*. 2011;12:3368.

58. Bahig H, de Guise J, Vu T, et al, Analysis of pulmonary vein antrums motion with cardiac contraction using dual-source computed tomography. *Cureus*. 2016;8:e712.

59. Ouyang ZI, Schoenhagen P, Wazni O, et al, Analysis of cardiac motion without respiratory motion for cardiac stereotactic body radiation therapy. *J Appl Clin Med Phys*. 2020;21:48–55.

60. Bert C, Grözing SO, Rietzel E. Quantification of interplay effects of scanned particle beams and moving targets. *Phys Med Biol*. 2008;53:2253–2265.

61. Constantinescu A, Lehmann HI, Packer DL, Bert C, Durante M, Graeff C. Treatment planning studies in patient data with scanned carbon ion beams for catheter-free ablation of atrial fibrillation. *J Cardiovasc Electrophysiol*. 2016;27:335–344.

62. Inoue T, Widder J, van Dijk LV, et al, Limited impact of setup and range uncertainties, breathing motion, and interplay effects in robustly optimized intensity modulated proton therapy for stage III non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2016;96:661–669.